Daratumumab (Darzalex®) Treatment Survey

Myeloma Canada is conducting a survey of “people living with myeloma who have used, or would like to use, daratumumab (Darzalex®) administered by a subcutaneous injection – where a needle is inserted just under the skin - rather than by infusion or intravenous.”

The survey is open until May 31, 2020 and is estimated to take 20 minutes to complete. Find out more and help further this research by participating in the survey.

If you have any questions, please email contact@myeloma.ca and include “Patient Survey” in the subject line.